Claims for Patent: 8,093,219

Summary for Patent: 8,093,219

Title:	Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Abstract:	Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
Inventor(s):	Manetta; Vincent (Bordentown, NJ), Watkins; Gary R. (Piscataway, NJ)
Assignee:	Galderma S.A. (Cham, CH)
Application Number:	12/483,604
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,093,219
Patent Claims:	1. A regime or regimen for the treatment of rosacea, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: 6 to 20% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetostearyl alcohol, cetyl alcohol, stearyl alcohol, stearic acid, palmitostearic acid and self-emulsifiable wax; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of one or more gelling agents selected from the group consisting of carbomers, cellulose derivatives, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water; said emulsion being chemically stable over a period of time of 8 weeks. 2. A regime or regimen for the treatment of rosacea, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: 6 to 20% by weight of an oily phase comprising dimethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, stearyl alcohol, palmitostearic acid and self-emulsifiable wax; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of aluminum magnesium silicate gelling agent but excluding aluminum magnesium silicate/titanium dioxide/silica; and water; said emulsion being chemically stable over a period of time of 8 weeks. 3. A regime or regimen for the treatment of rosacea, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: 6 to 20% by weight of an oily phase comprising dimethicone and isopropyl palmitate, said oily phase further comprising fatty substances selected from the group consisting of palmitostearic acid, self-emulsifiable wax, cetyl alcohol and stearyl alcohol; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG stearate, sorbitan monostearate, Steareth-20 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, glyceryl triacetate, oleyl alcohol and phenoxyethanol; 0.01 to 5% by weight of aluminum magnesium silicate gelling agent but excluding aluminum magnesium silicate/titanium dioxide/silica; and water; said emulsion being chemically stable over a period of time of 8 weeks. 4. A regime or regimen for the treatment of rosacea, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin, said topical pharmaceutical composition being formulated as an emulsion, the topical pharmaceutical emulsion comprising: 6 to 20% by weight of an oily phase comprising dimethicone, isopropyl palmitate, palmitostearic acid and self-emulsifiable wax; 2 to 12% by weight of glyceryl/PEG stearate, sorbitan monostearate and Steareth-20 as surfactant-emulsifiers; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of the solvents and/or propenetrating agents propylene glycol, glyceryl triacetate and phenoxyethanol; 0.01 to 5% by weight of aluminum magnesium silicate gelling agent but excluding aluminum magnesium silicate/titanium dioxide/silica; and water; said emulsion being chemically stable over a period of time of 8 weeks. 5. The regime or regimen as defined by claim 1, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants. 6. The regime or regimen as defined by claim 1, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide. 7. The regime or regimen as defined by claim 2, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants. 8. The regime or regimen as defined by claim 2, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide. 9. The regime or regimen as defined by claim 3, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants. 10. The regime or regimen as defined by claim 3, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide. 11. The regime or regimen as defined by claim 4, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants. 12. The regime or regimen as defined by claim 4, said topical pharmaceutical composition further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide. 13. The regime or regimen as defined by claim 4, further comprising glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide. 14. A topically applicable stable pharmaceutical emulsion comprising: 6 to 20% by weight of an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetostearyl alcohol, cetyl alcohol, stearyl alcohol, stearic acid, palmitostearic acid and self-emulsifiable wax; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of one or more gelling agents selected from the group consisting of carbomers, cellulose derivatives, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water; said emulsion being chemically stable over a period of time of 8 weeks. 15. A topically applicable stable pharmaceutical emulsion, comprising: 6 to 20% by weight of an oily phase comprising dimethicone, isopropyl palmitate and/or isopropyl myristate, said oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, stearyl alcohol, palmitostearic acid and self-emulsifiable wax; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; 0.01 to 5% by weight of aluminum magnesium silicate gelling agent but excluding aluminum magnesium silicate/titanium dioxide/silica; and water; said emulsion being chemically stable over a period of time of 8 weeks. 16. A topically applicable, stable pharmaceutical emulsion, comprising: 6 to 20% by weight of an oily phase comprising dimethicone and isopropyl palmitate, said oily phase further comprising fatty substances selected from the group consisting of palmitostearic acid, self-emulsifiable wax, cetyl alcohol and stearyl alcohol; 2 to 12% by weight of at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG stearate, sorbitan monostearate, Steareth-20 and Ceteareth-20; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, glyceryl triacetate and phenoxyethanol; 0.01 to 5% by weight of aluminum magnesium silicate gelling agent but excluding aluminum magnesium silicate/titanium dioxide/silica; and water; said emulsion being chemically stable over a period of time of 8 weeks. 17. A topically applicable, pharmaceutical emulsion, comprising: 6 to 20% by weight of an oily phase comprising dimethicone, isopropyl palmitate, palmitostearic acid and self-emulsifiable wax; 2 to 12% by weight of glyceryl/PEG stearate, sorbitan monostearate and Steareth-20 as surfactant-emulsifiers; 0.1 to 5% by weight of ivermectin; 1 to 10% by weight of a mixture of the solvents and/or propenetrating agents propylene glycol, glyceryl triacetate and phenoxyethanol; 0.01 to 5% by weight of aluminum magnesium silicate gelling agent but excluding aluminum magnesium silicate/titanium dioxide/silica; and water; said emulsion being chemically stable over a period of time of 8 weeks. 18. The topically applicable, stable pharmaceutical emulsion as defined by claim 14, further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants. 19. The topically applicable, stable pharmaceutical emulsion as defined by claim 14, further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide. 20. The topically applicable, stable pharmaceutical emulsion as defined by claim 15, further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants. 21. The topically applicable, stable pharmaceutical emulsion as defined by claim 15, further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide. 22. The topically applicable, stable pharmaceutical emulsion as defined by claim 16, further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants. 23. The topically applicable, stable pharmaceutical emulsion as defined by claim 16, further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide. 24. The topically applicable, stable pharmaceutical emulsion as defined by claim 17, further comprising one or more additives selected from the group consisting of flavor enhancers, preserving agents, stabilizers, humidity regulators, pH regulators, osmotic pressure modifiers, UV-A screening agents, UV-B screening agents and antioxidants. 25. The topically applicable, stable pharmaceutical emulsion as defined by claim 17, further comprising one or more additives selected from the group consisting of glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide. 26. The topically applicable, stable pharmaceutical emulsion as defined by claim 17, further comprising glycerol, methyl para-hydroxybenzoate, disodium EDTA, citric acid monohydrate, propyl para-hydroxybenzoate and sodium hydroxide. 27. The topically applicable stable pharmaceutical emulsion as defined by claim 15, comprising: TABLE-US-00010 Ivermectin 1.00 Glycerol 4.0 Aluminum magnesium silicate 1.0 Methyl para-hydroxybenzoate 0.2 Disodium EDTA 0.05 Citric acid monohydrate 0.05 Isopropyl palmitate 4.0 Glyceryl/PEG 100 stearate 3.0 Self-emulsifiable wax 2.0 Palmitostearic acid 2.5 Steareth-20 3.0 Sorbitan stearate 2.0 Dimethicone 20 0.5 Propyl para-hydroxybenzoate 0.1 Propylene glycol 4.0 Glyceryl triacetate 1.0 Phenoxyethanol 0.5 10% sodium hydroxide qs pH Water qs 100 as % by weight relative to the total weight of the composition. 28. The topically applicable, stable pharmaceutical emulsion as defined by claim 15, comprising: TABLE-US-00011 Ivermectin 1.00 Glycerol 4.0 Aluminum magnesium silicate 1.0 Methyl para-hydroxybenzoate 0.2 Disodium EDTA 0.05 Citric acid monohydrate 0.05 Isopropyl palmitate 4.0 Glyceryl/PEG 100 stearate 3.0 Self-emulsifiable wax 2.0 Palmitostearic acid 3.0 Steareth-20 3.0 Sorbitan stearate 2.0 Dimethicone 20 0.5 Propyl para-hydroxybenzoate 0.1 Propylene glycol 4.0 Glyceryl triacetate 1.0 Phenoxyethanol 0.5 10% sodium hydroxide qs pH Water qs 100 as % by weight relative to the total weight of the composition. 29. The regime or regimen as defined by claim 2, said topical pharmaceutical emulsion comprising: TABLE-US-00012 Ivermectin 1.00 Glycerol 4.0 Aluminum magnesium silicate 1.0 Methyl para-hydroxybenzoate 0.2 Disodium EDTA 0.05 Citric acid monohydrate 0.05 Isopropyl palmitate 4.0 Glyceryl/PEG 100 stearate 3.0 Self-emulsifiable wax 2.0 Palmitostearic acid 2.5 Steareth-20 3.0 Sorbitan stearate 2.0 Dimethicone 20 0.5 Propyl para-hydroxybenzoate 0.1 Propylene glycol 4.0 Glyceryl triacetate 1.0 Phenoxyethanol 0.5 10% sodium hydroxide qs pH Water qs 100 as % by weight relative to the total weight of the composition. 30. The regime or regimen as defined by claim 2, said topical pharmaceutical emulsion comprising: TABLE-US-00013 Ivermectin 1.00 Glycerol 4.0 Aluminum magnesium silicate 1.0 Methyl para-hydroxybenzoate 0.2 Disodium EDTA 0.05 Citric acid monohydrate 0.05 Isopropyl palmitate 4.0 Glyceryl/PEG 100 stearate 3.0 Self-emulsifiable wax 2.0 Palmitostearic acid 3.0 Steareth-20 3.0 Sorbitan stearate 2.0 Dimethicone 20 0.5 Propyl para-hydroxybenzoate 0.1 Propylene glycol 4.0 Glyceryl triacetate 1.0 Phenoxyethanol 0.5 10% sodium hydroxide qs pH Water qs 100 as % by weight relative to the total weight of the composition.